Last 690.70 INR
Change Today +9.45 / 1.39%
Volume 39.6K
HCBA On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:27 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

novartis india ltd (HCBA) Snapshot

Open
681.65
Previous Close
681.25
Day High
700.00
Day Low
681.65
52 Week High
07/22/14 - 720.40
52 Week Low
09/3/13 - 361.00
Market Cap
22.1B
Average Volume 10 Days
25.3K
EPS TTM
30.83
Shares Outstanding
32.0M
EX-Date
07/16/14
P/E TM
22.4x
Dividend
10.00
Dividend Yield
1.45%
Current Stock Chart for NOVARTIS INDIA LTD (HCBA)

Related News

No related news articles were found.

novartis india ltd (HCBA) Related Businessweek News

No Related Businessweek News Found

novartis india ltd (HCBA) Details

Novartis India Limited manufactures and sells healthcare products in India and internationally. It operates through four segments: Pharmaceuticals, Generics, Over-The-Counter, and Animal Health. The Pharmaceuticals segment offers a portfolio of prescription medicines in various therapeutic areas, including central nervous system, pain and inflammation, and transplantation/immunology through healthcare professionals primarily under the Voveran, Trioptal, Exelon, Tegrital, and Sandimmun Neoral brand names. This segment offers its products in various forms, such as tablets, capsules, liquid orals, injectables, creams and ointments, patches, and vials. The Generics segment offers retail generics products in various therapeutic areas, such as anti-TB, anti-DUB (gynecology), anti-histamines, antibiotics, anti-ulcerants, anti-diabetes, and cardiovascular. This segment offers its products in tablet and liquid-oral forms. The Over-The-Counter segment offers vitamins, minerals, and nutritional supplements, as well as products for the treatment of cough, cold, and allergy primarily under the Otrivin, Otrinoz, and T-minic brand names. It offers its products in various forms, which include powders-vitamin and nutritional supplements, tablets, capsules, and liquid-orals. The Animal Health segment offers drug formulations and feed supplements in cattle and poultry markets. The company was founded in 1947 and is based in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.

1,294 Employees
Last Reported Date: 06/30/14
Founded in 1947

novartis india ltd (HCBA) Top Compensated Officers

Vice Chairman, Managing Director and Member o...
Total Annual Compensation: 16.8M
Compensation as of Fiscal Year 2014.

novartis india ltd (HCBA) Key Developments

Novartis India Limited Reports Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2014

Novartis India Limited reported audited standalone earnings results for the fourth quarter and full year ended March 31, 2014. For the quarter, the company reported net sales of INR 1,930.3 million, profit from operations before other income, finance costs and exceptional items of INR 65.1 million, profit from ordinary activities before tax of INR 322.6 million, net profit for the period of INR 238.8 million or INR 7.47 per basic and diluted share against net sales of INR 2,079.5 million, loss from operations before other income, finance costs and exceptional items of INR 75.1 million, loss from ordinary activities before tax of INR 297.6 million, net loss for the period of INR 244.1 million or INR 7.64 per diluted share for the same period last year. For the full year, the company reported net sales of INR 8,397.8 million, loss from operations before other income, finance costs and exceptional items of INR 48.9 million, profit from ordinary activities before tax of INR 899.0 million, net profit for the period of INR 985.3 million or INR 30.83 per basic and diluted share against net sales of INR 8,861.0 million, profit from operations before other income, finance costs and exceptional items of INR 864.5 million, profit from ordinary activities before tax of INR 1,694.2 million, net profit for the period of INR 1,197.3 million or INR 37.46 per diluted share for the same period last year.

Novartis India Ltd Approves Dividend Recommendation for the Year Ended March 31, 2014; Announces Board Changes

Novartis India Ltd. informed that the board of directors of the company at its meeting held on May 22, 2014, has considered and approved the dividend recommendation of INR 10 per equity share of INR 5 each for the year ended March 31, 2014. The board also approved the appointment of Ms. Manisha Girotra as additional director on the board of directors of the company who shall hold office up to the date of the next annual general meeting of the company and also approved the appointment of Mr. Dinesh Charak as Additional director and whole time director on the board of directors of the company who shall hold office up to the date of the next AGM of the company.

Novartis India Limited, Board Meeting, May 22, 2014

Novartis India Limited, Board Meeting, May 22, 2014. Agenda: To consider the audited standalone earnings results for the fourth quarter and full year ended March 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HCBA:IN 690.70 INR +9.45

HCBA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HCBA.
View Industry Companies
 

Industry Analysis

HCBA

Industry Average

Valuation HCBA Industry Range
Price/Earnings 22.7x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 21.8x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS INDIA LTD, please visit www.novartis.in/. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.